German pharmaceutical company CureVac has developed the CVnCoV vaccine candidate formulation, which is currently in two clinical trials in phases 2/3 and 3, to evaluate its efficacy, security and immunogenicity. The company announced on April 19 that they had initiated the procedures for seeking approval. It is an injection of messenger RNA that carries the “instructions” to make the Spike (S) protein, a technology similar to both Pfizer/BioNTech and Moderna. However, unlike its competitors, the RNA to be injected has been developed with natural nucleotides (which form the bases of the genetic material) and no from artificial ones as the other two vaccines made with this technology. Like Pfizer and Moderna vaccines, CVnCoV is tested with a cell line, in this case with tumor origin and not embryonic as the other two.
This content is restricted to site members. If you are an existing user, please log in. New users may register below.